Trial Profile
A 26-week, Randomised, Open-labelled, Two-arm, Parallel-group, Treat-to-target Trial Comparing Efficacy and Safety of Soluble Insulin Analogue Combination (SIAC) Twice Daily (BID) With Biphasic Insulin Aspart (BIAsp) 30 BID, With or Without Metformin, With or Without DPP-4 Inhibitor, With or Without Pioglitazone in Subjects With Type 2 Diabetes in Inadequate Glycaemic Control on Once or Twice Daily Premixed or Self-mixed Insulin Regimen With or Without OADs (BOOST: Intensify Premix 1)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Insulin degludec/insulin aspart (Primary) ; Insulin aspart/insulin protamine aspart
- Indications Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Acronyms BOOST; BOOST-INTENSIFY-PREMIX-1
- Sponsors Novo Nordisk
- 01 Dec 2016 Results of pooled data of cost-effectiveness analysis from two phase III studies (BOOST-INTENSIFY-ALL and BOOST-INTENSIFY-PREMIX-1) published in the Diabetes Therapy
- 01 Dec 2015 Post-hoc pooled analysis results presented at the 23rd World Diabetes Congress of the International Diabetes Federation (IDF), as per Novo Nordisk media release.
- 08 May 2014 Results published in the Diabetes Care.